EP2968246A4 - Omega-3 pentaenoic acid compositions and methods of use - Google Patents

Omega-3 pentaenoic acid compositions and methods of use

Info

Publication number: EP2968246A4
Authority: EP; European Patent Office
Prior art keywords: omega; methods; acid compositions; pentaenoic acid; pentaenoic
Prior art date: 2013-03-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP13878433.5A

Other languages

German (de)

French (fr)

Other versions

EP2968246A1 (en

Inventor

Abdel Aziz Fawzy

George Bobotas

Roelof Rongen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Matinas Biopharma Inc

Original Assignee

Matinas Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-13

Filing date

2013-12-17

Publication date

2016-08-03

2013-12-17 Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc

2016-01-20 Publication of EP2968246A1 publication Critical patent/EP2968246A1/en

2016-08-03 Publication of EP2968246A4 publication Critical patent/EP2968246A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Neurology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Edible Oils And Fats (AREA)

EP13878433.5A 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use Withdrawn EP2968246A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361780948P	2013-03-13	2013-03-13
PCT/US2013/075661 WO2014143272A1 (en)	2013-03-13	2013-12-17	Omega-3 pentaenoic acid compositions and methods of use

Publications (2)

Publication Number	Publication Date
EP2968246A1 EP2968246A1 (en)	2016-01-20
EP2968246A4 true EP2968246A4 (en)	2016-08-03

Family

ID=51537458

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP13878433.5A Withdrawn EP2968246A4 (en)	2013-03-13	2013-12-17	Omega-3 pentaenoic acid compositions and methods of use
EP14779339.2A Withdrawn EP2986148A2 (en)	2013-03-13	2014-03-12	Compositions comprising docosapentaenoic acid and methods of use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP14779339.2A Withdrawn EP2986148A2 (en)	2013-03-13	2014-03-12	Compositions comprising docosapentaenoic acid and methods of use

Country Status (4)

Country	Link
EP (2)	EP2968246A4 (en)
JP (2)	JP2016518315A (en)
CA (2)	CA2905671A1 (en)
WO (4)	WO2014143272A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2934132T3 (en) *	2014-12-15	2023-02-17	Dsm Ip Assets Bv	Treatment for non-alcoholic fatty liver disease
CN116492339A (en) *	2015-11-13	2023-07-28	深圳君圣泰生物技术有限公司	Composition, application thereof and pharmaceutical preparation
EP3456328A4 (en) *	2016-05-10	2020-02-26	Shenzhen Hightide Biopharmaceutical., Ltd.	Composition, and application and pharmaceutical preparation thereof
WO2018146545A1 (en) *	2017-02-09	2018-08-16	S.L.A. Pharma Ag	Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in ulcerative colitis patients
CN107006809B (en) *	2017-04-11	2020-06-09	江南大学	Vinegar onion product with blood fat reducing effect and preparation method thereof
JP7099821B2 (en) *	2017-12-20	2022-07-12	ポッカサッポロフード＆ビバレッジ株式会社	PCSK9 inhibitor and food composition for improving cholesterol metabolism

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1714564A1 (en) *	2005-04-21	2006-10-25	N.V. Nutricia	Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) *	2006-09-14	2008-03-20	Ilshin Wells Co., Ltd.	Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) *	2009-03-11	2011-03-24	Stable Solutions Llc	Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) *	2012-06-17	2013-12-27	Matinas Biopharma, Inc.	Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070104856A1 (en) *	2003-05-05	2007-05-10	Hakon Standal	Fish oils with an altered fatty acid profile, method of producing same and their use
EP1656839A1 (en) *	2004-11-11	2006-05-17	N.V. Nutricia	Nutrition containing lipid blend
CA2588166A1 (en) *	2004-11-19	2006-05-26	Martek Biosciences Corporation	Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2007058523A1 (en) *	2005-11-17	2007-05-24	N.V. Nutricia	Composition with docosapentaenoic acid
WO2010093634A1 (en) *	2009-02-10	2010-08-19	Amarin Pharma, Inc.	Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
KR101841756B1 (en) *	2009-03-09	2018-03-23	프로노바 바이오파마 너지 에이에스	Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
CN102413825A (en) *	2009-04-29	2012-04-11	阿马里纳股份公司	Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US20110177061A1 (en) *	2009-07-10	2011-07-21	Martek Biosciences Corporation	Methods of treating and preventing neurological disorders using docosahexaenoic acid
EP2493478B8 (en) *	2009-10-29	2018-03-28	Acasti Pharma, Inc.	Concentrated therapeutic phospholipid compositions
US20120302639A1 (en) *	2011-02-16	2012-11-29	Pivotal Therapeutics Inc.	Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
WO2013033618A1 (en) *	2011-09-02	2013-03-07	Arctic Nutrition As	Lipid compositions with high dha content

2013
- 2013-12-17 EP EP13878433.5A patent/EP2968246A4/en not_active Withdrawn
- 2013-12-17 JP JP2016500125A patent/JP2016518315A/en active Pending
- 2013-12-17 CA CA2905671A patent/CA2905671A1/en not_active Abandoned
- 2013-12-17 WO PCT/US2013/075661 patent/WO2014143272A1/en active Application Filing
- 2013-12-17 WO PCT/US2013/075704 patent/WO2014158256A1/en active Application Filing
- 2013-12-17 WO PCT/US2013/075740 patent/WO2014143275A1/en active Application Filing
2014
- 2014-03-12 EP EP14779339.2A patent/EP2986148A2/en not_active Withdrawn
- 2014-03-12 JP JP2016501615A patent/JP2016512544A/en active Pending
- 2014-03-12 WO PCT/US2014/024712 patent/WO2014165190A2/en active Application Filing
- 2014-03-12 CA CA2905795A patent/CA2905795A1/en not_active Abandoned

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1714564A1 (en) *	2005-04-21	2006-10-25	N.V. Nutricia	Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) *	2006-09-14	2008-03-20	Ilshin Wells Co., Ltd.	Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) *	2009-03-11	2011-03-24	Stable Solutions Llc	Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) *	2012-06-17	2013-12-27	Matinas Biopharma, Inc.	Omega-3 pentaenoic acid compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014143272A1 *

Also Published As

Publication number	Publication date
WO2014158256A1 (en)	2014-10-02
WO2014165190A2 (en)	2014-10-09
CA2905671A1 (en)	2014-09-18
EP2986148A2 (en)	2016-02-24
JP2016512544A (en)	2016-04-28
WO2014143275A1 (en)	2014-09-18
CA2905795A1 (en)	2014-10-09
JP2016518315A (en)	2016-06-23
WO2014143272A1 (en)	2014-09-18
WO2014165190A3 (en)	2015-01-29
EP2968246A1 (en)	2016-01-20

Publication	Publication Date	Title
EP2861227A4 (en)	2016-01-27	Omega-3 pentaenoic acid compositions and methods of use
HK1213023A1 (en)	2016-06-24	Compositions and methods of nucleic acid-targeting nucleic acids
IL265876A (en)	2019-06-30	Compositions comprising 15-ohepa and methods of using the same
HK1211866A1 (en)	2016-06-03	Antioxidant compositions and methods of using the same
IL245550A0 (en)	2016-06-30	Compositions and methods of using transposons
EP3735963C0 (en)	2023-09-13	Self-emulsifying composition of omega-3 fatty acid
SG11201600337PA (en)	2016-02-26	SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
HK1214171A1 (en)	2016-07-22	Cenicriviroc compositions and methods of making and using the same
EP2953474A4 (en)	2016-12-28	Compositions and methods
GB201313423D0 (en)	2013-09-11	Compositions and methods
EP2964235A4 (en)	2016-11-09	Antimicrobial-antibiofilm compositions and methods of use thereof
GB201308072D0 (en)	2013-06-12	Compositions and methods
HK1221416A1 (en)	2017-06-02	Formulations of oxabicycloheptanes and oxabicycloheptenes
PL2997117T3 (en)	2019-08-30	Use of an ester
SG11201602331QA (en)	2016-04-28	Compositions and methods utilizing lysophosphatidylcholine scaffolds
GB201305813D0 (en)	2013-05-15	Compositions and methods
SG11201505891VA (en)	2015-08-28	Catalyst compositions and methods of making and using same
EP2968246A4 (en)	2016-08-03	Omega-3 pentaenoic acid compositions and methods of use
IL245588A0 (en)	2016-06-30	Solid compositions of triglycerides and uses thereof
EP2964610A4 (en)	2016-11-23	Vinylsulfone-based 18f-labeling compositions and methods and uses thereof
IL240734A0 (en)	2015-10-29	Methods and compositions for preparation of nucleic acids
EP2929041A4 (en)	2016-06-08	Omega-3 pentaenoic acid compositions and methods of use
ZA201505825B (en)	2019-04-24	Coating compositions and methods of use
GB201300628D0 (en)	2013-02-27	Compositions comprising 15-OHEPA and methods of using the same
GB201310349D0 (en)	2013-07-24	Composition and method of use thereof

Legal Events

Date	Code	Title	Description
2015-12-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-01-20	17P	Request for examination filed	Effective date: 20150930
2016-01-20	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-01-20	AX	Request for extension of the european patent	Extension state: BA ME
2016-06-22	DAX	Request for extension of the european patent (deleted)
2016-08-03	A4	Supplementary search report drawn up and despatched	Effective date: 20160704
2016-08-03	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/232 20060101ALI20160628BHEP Ipc: A61K 31/202 20060101AFI20160628BHEP Ipc: A61K 9/48 20060101ALI20160628BHEP
2017-06-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2017-07-26	18D	Application deemed to be withdrawn	Effective date: 20170201